A phase III trial is comparing the efficacy of pembrolizumab alone versus in combination with chemotherapy as first-line treatment for stage IV non-squamous non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.

ClinicalJune 17, 2026

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.

ClinicalJune 17, 2026

Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy

The study evaluates calderasib combined with pembrolizumab as a first-line treatment for KRAS G12C mutant NSCLC.

CompetitiveJune 16, 2026

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.

ClinicalJune 16, 2026

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.

ClinicalJune 16, 2026

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

NSCLC →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.